Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data in Phase 1a Dose Escalation for JANX007 in mCRPC and Doses Selected for Phase 1b Expansion Studies
Janux Therapeutics (NASDAQ: JANX) announced a virtual event scheduled for December 2, 2024, at 4:30 PM ET to discuss updated clinical data from JANX007's Phase 1a dose escalation trial in metastatic castration-resistant prostate cancer (mCRPC) patients. The company will also reveal doses selected for Phase 1b expansion studies. The event will feature CEO David Campbell and include a Q&A session. JANX007 is the company's first clinical TRACTr candidate targeting PSMA, while their second candidate, JANX008, targets EGFR for multiple solid cancers.
Janux Therapeutics (NASDAQ: JANX) ha annunciato un evento virtuale programmato per il 2 dicembre 2024 alle 16:30 ET per discutere dati clinici aggiornati dalla sperimentazione clinica di fase 1a del farmaco JANX007 nel trattamento dei pazienti con cancro alla prostata resistente alla castrazione metastatico (mCRPC). L'azienda rivelerà anche le dosi selezionate per gli studi di espansione della fase 1b. L'evento vedrà la partecipazione del CEO David Campbell e includerà una sessione di domande e risposte. JANX007 è il primo candidato clinico TRACTr dell'azienda mirato al PSMA, mentre il loro secondo candidato, JANX008, è indirizzato all'EGFR per diversi tipi di cancro solido.
Janux Therapeutics (NASDAQ: JANX) anunció un evento virtual programado para el 2 de diciembre de 2024 a las 4:30 PM ET para discutir datos clínicos actualizados del ensayo de escalamiento de dosis de fase 1a de JANX007 en pacientes con cáncer de próstata resistente a la castración metastásico (mCRPC). La compañía también revelará las dosis seleccionadas para los estudios de expansión de fase 1b. El evento contará con la participación del CEO David Campbell e incluirá una sesión de preguntas y respuestas. JANX007 es el primer candidato clínico TRACTr de la empresa dirigido al PSMA, mientras que su segundo candidato, JANX008, se enfoca en el EGFR para múltiples cánceres sólidos.
Janux Therapeutics (NASDAQ: JANX)는 2024년 12월 2일 오후 4시 30분 ET에 가상 이벤트를 개최하여 JANX007의 1상 약물 용량 상승 시험에서의 업데이트된 임상 데이터에 대해 논의할 것이라고 발표했습니다. 회사는 또한 1b 단계 확장 연구를 위한 선택된 용량을 공개할 것입니다. 이 이벤트는 CEO David Campbell이 참석하며 Q&A 세션을 포함할 예정입니다. JANX007은 PSMA를 타겟으로 하는 회사의 첫 번째 임상 TRACTr 후보 물질이며, 두 번째 후보인 JANX008은 여러 고형 암을 위한 EGFR을 타겟으로 하고 있습니다.
Janux Therapeutics (NASDAQ: JANX) a annoncé un événement virtuel prévu pour le 2 décembre 2024 à 16h30 ET pour discuter des données cliniques mises à jour de l'essai d'escalade de dose de phase 1a de JANX007 chez des patients atteints de cancer de la prostate métastatique résistant à la castration (mCRPC). L'entreprise révélera également les doses sélectionnées pour les études d'expansion de phase 1b. L'événement mettra en vedette le PDG David Campbell et comprendra une session de questions-réponses. JANX007 est le premier candidat clinique TRACTr de l'entreprise ciblant le PSMA, tandis que leur deuxième candidat, JANX008, cible l'EGFR pour plusieurs cancers solides.
Janux Therapeutics (NASDAQ: JANX) kündigte eine virtuelle Veranstaltung für den 2. Dezember 2024 um 16:30 Uhr ET an, um aktualisierte klinische Daten aus der Phase-1a-Dosiserhöhung von JANX007 bei Patienten mit metastasierendem kastrationsresistentem Prostatakrebs (mCRPC) zu besprechen. Das Unternehmen wird auch die für die Phase-1b-Erweiterungsstudien ausgewählten Dosen bekannt geben. Die Veranstaltung wird von CEO David Campbell geleitet und umfasst eine Frage- und Antwortsitzung. JANX007 ist der erste klinische TRACTr-Kandidat des Unternehmens, der auf PSMA abzielt, während der zweite Kandidat, JANX008, EGFR für mehrere solide Tumoren anvisiert.
- Phase 1a dose escalation trial for JANX007 has progressed to dose selection for Phase 1b
- Company advancing pipeline with two clinical-stage candidates (JANX007 and JANX008)
- None.
Insights
This future virtual event announcement about JANX007 Phase 1a data represents a standard corporate communication without immediate market impact. While clinical data updates are important for biotech companies, this release only announces a future presentation without revealing actual results. The event, scheduled for December 2024, will discuss dose selection for Phase 1b expansion studies in metastatic castration-resistant prostate cancer (mCRPC), but without current data disclosure, it's premature to assess its significance.
The company's pipeline focus on TRACTr and TRACIr platforms, particularly JANX007 targeting PSMA and JANX008 targeting EGFR, shows promising potential. However, this event announcement alone doesn't provide actionable information for investors. Material impact would come from the actual data presentation in December 2024.
The virtual event will take place on Monday, December 2, 2024, at 4:30 PM ET
David
A live question and answer session will follow the formal presentation. To register for the event, please click here.
Participant Dial-In Details:
International - 1 (646) 307-1963
Conference ID: 2229349
Janux’s TRACTr and TRACIr Pipeline
Janux’s first clinical candidate, JANX007, is a TRACTr that targets PSMA and is being investigated in a Phase 1 clinical trial in adult subjects with metastatic castration-resistant prostate cancer (mCRPC). Janux’s second clinical candidate, JANX008, is a TRACTr that targets EGFR and is being studied in a Phase 1 clinical trial for the treatment of multiple solid cancers including colorectal carcinoma, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma and triple-negative breast cancer. We are also generating a number of additional TRACTr and TRACIr programs for potential future development, some of which are at development candidate stage or later. We are currently assessing priorities in our preclinical pipeline.
About Janux Therapeutics
Janux is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Janux’s proprietary technology enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The goal of both platforms is to provide cancer patients with safe and effective therapeutics that direct and guide their immune system to eradicate tumors while minimizing safety concerns. Janux is currently developing a broad pipeline of TRACTr and TRACIr therapeutics directed at several targets to treat solid tumors. Janux has two TRACTr therapeutic candidates in clinical trials, the first targeting PSMA is in development for prostate cancer, and the second targeting EGFR is being developed for colorectal carcinoma, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma and triple-negative breast cancer. For more information, please visit www.januxrx.com and follow us on LinkedIn.
Forward-Looking Statements
This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, Janux’s ability to bring new treatments to cancer patients in need and expectations regarding the timing, scope and results of Janux’s development activities. Factors that may cause actual results to differ materially include the risk that compounds that appear promising in early research do not demonstrate safety and/or efficacy in later preclinical studies or clinical trials, the risk that Janux may not obtain approval to market its product candidates, uncertainties associated with performing clinical trials, regulatory filings and applications, risks associated with reliance on third parties to successfully conduct clinical trials, the risks associated with reliance on outside financing to meet capital requirements, and other risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. You are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “believes,” “estimates,” “projects,” “promise,” “potential,” “expects,” “plans,” “anticipates,” “intends,” “continues,” “designed,” “goal,” or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties Janux faces, please refer to Janux’s periodic and other filings with the Securities and Exchange Commission, which are available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and Janux assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241125381273/en/
Investors:
Andy Meyer
Janux Therapeutics
ameyer@januxrx.com
(202) 215-2579
Media:
Jessica Yingling, Ph.D.
Little Dog Communications Inc.
jessica@litldog.com
(858) 344-8091
Source: Janux Therapeutics
FAQ
When will Janux Therapeutics (JANX) host its virtual event for JANX007 clinical data?
What will be discussed during Janux Therapeutics' (JANX) December 2024 virtual event?
What type of cancer is JANX007 targeting in its clinical trials?
